Search
for
Sort by
Research 481–510 of 519
- Rapid hair regrowth in an alopecia universalis patient with deucravacitinib: A case report
- Off-Label Treatment of Alopecia Areata—Retrospective Study
- Reversal of Alopecia Areata Following Treatment With the JAK1/2 Inhibitor Baricitinib
- Biomarkers of alopecia areata disease activity and response to corticosteroid treatment
- Efficacy and safety of the oral Janus kinase 3/tyrosine kinase expressed in hepatocellular carcinoma family kinase inhibitor ritlecitinib over 24 months: integrated analysis of the ALLEGRO phase IIb/III and long-term phase III clinical studies in alopecia areata
- Palmoplantar pustulosis–like eruption following tofacitinib therapy for juvenile idiopathic arthritis
- Sustained hair regrowth with continued ritlecitinib treatment through week 48 in patients with alopecia areata with or without early target responses: Post hoc analysis of the ALLEGRO phase 2b/3 trial
- Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy
- Safety and Efficacy of Ritlecitinib for the Treatment of Patients with Alopecia Areata: A Systematic Review and Meta-Analysis of Controlled Trials
- Topical tofacitinib for patients with lichen planopilaris and/or frontal fibrosing alopecia
- Efficacy and safety of deuruxolitinib, an oral selective Janus kinase 1/2 inhibitor, in adults with alopecia areata: Results from the THRIVE-AA2 Phase 3, randomized, double-blind, controlled trial
- 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
- The relative efficacy of monotherapy with Janus kinase inhibitors, dupilumab and apremilast in adults with alopecia areata: Network meta‐analyses of clinical trials
- Adverse events in patients treated with Jak‐inhibitors for alopecia areata: A systematic review
- Improvement in Patient‐Reported Emotional Symptoms and Activity Limitations due to Hair Loss in Patients With Alopecia Areata Treated With Ritlecitinib: Additional Analyses From ALLEGRO ‐2b/3
- The Diverse Experiences and Challenges of Individuals With Alopecia Areata: Survey Results From Finland
- The first 20 years of skin of color dermatology: An era of advancements in skin, hair, and nail disorders
- Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review
- Unveiling a Shared Precursor Condition for Acne Keloidalis Nuchae and Primary Cicatricial Alopecias
- Incidence Rates of Infections, Malignancies, Thromboembolism, and Cardiovascular Events in an Alopecia Areata Cohort from a US Claims Database
- Alopecia Areata in Skin of Color Patients: New Considerations Sparked by the Approval of Baricitinib
- Dermatologists’ Perspectives and Real-World Assessment of Alopecia Areata Severity, Burden, and Healthcare Resource Utilization in Adults in the United Arab Emirates
- Real-world Burden of Disease and Clinical Characteristics of Alopecia Areata Among Adults in Brazil: Results from a Cross-sectional Survey
- 0527 Effectiveness of janus kinase inhibitor for rapidly progressive acute alopecia areata
- Oral tofacitinib for recalcitrant lichen planus pigmentosus: A hospital-based retrospective study
- <div>Six years of the IP Indian Journal of Clinical and Experimental Dermatology (2019-2025):&nbsp;<span style="font-size: 1rem;">A bibliometric and thematic analysis</span></div>
- Risk of Safety Events in Vitiligo Patients: A Retrospective Real‐World Data Study in the US
- Theoretical investigation on the construction of hair follicle membranes and the transdermal drug delivery mechanisms of JAK inhibitors via distinct pathways
- Unlocking the Potential of Rosemary in Alopecia: A Narrative Review of Evidence on Mechanism, Applications and Challenges
- Rates of Infections, Malignancies, Cardiovascular Outcomes, and Death in Individuals with Hospital-treated Alopecia Areata: A Registry-based Cohort Study in Denmark